NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

NWBO is also comparing treatment to placebo. I’d think you and ex wouldn’t have to be told that nine billion times.

The trial, like most all trials, has many secondary and tertiary endpoints. But the trial passes or fails with the primary (or more precisely, however the alpha is assigned).

If they do change the endpoints in the analysis, then they can properly say they trial worked if it meets the OS against historical trials endpoint.

The FDA would not fall for that game, but a subset of investors will.